(Albany, US) DelveInsight launched a new report on “‘Dry eye disease – Epidemiology Forecast to 2030”.
DelveInsight’s ‘Dry eye disease – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Dry eye disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the facts of the report
1. As per DelveInsight estimates, market size for EU5 was USD 602.62 million in 2017.
2. As per DelveInsight analysis, it is observed that, Germany had the highest prevalent population of Dry Eye Disease in EU5.
3. DelveInsight’s Analysis, it can be observed that Dry Eye Disease cases among the age group 46–65 years are far higher in number than other age groups. It can also be observed that patients below 17 years are least prone to DED.
4. As per Delveinsight’s estimates, the total prevalent population of Dry Eye Disease in EU5 was 11,939,169 in 2017
“ Among the Dry Eye Disease patients, Females accounts for a higher number of Dry Eye Disease cases than Males in 7MM.”
Dry Eye Disease, also known as Dry Eye Syndrome (DES) or Keratoconjunctivitis Sicca, is a common condition when eyes do not produce enough tears or the tears evaporate too quickly, that is essential to lubricate and nourish the eye. The condition leads to eyes drying out and becoming red, swollen, and irritated. Causes for DES include decreased tear production, excessive tear evaporation, and abnormality in the production of mucus or lipids of tear layer.
The disease management basically aims to relieve the discomfort and prevent the damage to the cornea, at the front of the eye. The currently available treatment options for Dry Eye Disease depend on the severity of the condition and may include medication, surgery, and others (eyelid therapy (warm compresses and eyelid hygiene, contact lenses, and moisture chamber spectacles)).
The main symptom of dry eyes is dry and gritty feeling in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain and redness of the eyes, and photophobia in some cases. Sometimes, it is also associated with a stringy discharge and blurred, changing vision. Symptoms are found to worsen in dry weathers, with low humidity and higher temperatures.
“ According to DelveInsight’s analysis, mild cases of Dry Eye Disease are more prominent in comparison to moderate and severe cases “
Request for sample pages : https://delveinsight.com/sample-request/dry-eye-disease-epidemiology-forecast
Dry eye disease Analytical Perspective by DelveInsight
- In-depth Dry eye disease Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Dry eye disease Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Dry eye disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Dry eye disease research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Dry eye disease.
Report highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Dry eye disease.
- In the coming years, the Dry eye disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Dry eye disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Dry eye disease treatment market. Several potential therapies for Dry eye disease are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Dry eye disease market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Dry eye disease) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making processregarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Request for sample pages : https://delveinsight.com/sample-request/dry-eye-disease-epidemiology-forecast
Key Questions
- What are the current options for Dry eye disease treatment?
- How many companies are developing therapies for the treatment of Dry eye disease?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Dry eye disease?
- How many Dry eye disease emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Dry eye disease?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Dry eye disease market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Dry eye disease?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Dry eye disease therapies?
- What are the clinical studies going on for Dry eye disease and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Dry eye disease?
- How many patents are granted and pending for the emerging therapies for the treatment of Dry eye disease?
Related Reports:
Dry eye disease – Pipeline Insights, 2020
The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.
Dry Eye Disease (DED) – Market Insight, Epidemiology and Market Forecast – 2028
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Dry Eye Disease (DED) from 2017 to 2028 segmented by seven major markets.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/